National Health Research Institutes (NHRI) and Jiayi Biomedical Co., Ltd. (Jiayi) have signed the technology transfer agreement in the end of June, 2021. Jiayi has granted the exclusive rights of the CXCR4 antagonist, DBPR215, with global patents.
DBPR215 is a stem cell mobilizer for cell-based therapy. It is a potential best-in-class drug which exhibited better efficacy and larger therapeutic index than Mozobil® (AMD3100) in animal models.
About Jiayi Biomedical Co., Ltd.
Jiayi is a start-up company established in Taiwan in 2019.
About IBPR of the NHRI
Institute of Biotechnology and Pharmaceutical Research of the NHRI is a mission-driven drug discovery and development engine with vertical and horizontal coordination and integration. For more information, visit https://ibpr.nhri.org.tw/en/ .